Carl read the papersWhat it actually is
Glow is a fixed combination of BPC-157, TB-500 and GHK-Cu, typically 70 mg of peptide in total per vial.
It is the same idea as KLOW without the KPV — the classic recovery pairing plus the copper peptide. The Glow name comes from the GHK-Cu component and its skin research, which is also the part most responsible for the blend's popularity.
How it’s thought to work
- BPC-157 — Local repair signalling — angiogenesis, fibroblast migration and gut lining protection.
- TB-500 — The systemic partner — actin regulation and cell migration, often described as acting body-wide rather than locally.
- GHK-Cu — Copper delivery for collagen synthesis and tissue remodelling — the skin component.
- Overlapping repair pathways — All three touch tissue repair from different angles, which is the argument for combining them. The one rat study that paired BPC-157 and TB-500 (2026) found no extra benefit over either alone.
What the research says
As with every blend, none on the combination itself. GHK-Cu carries the strongest individual research of the three, with a substantial literature on skin, collagen and wound healing. BPC-157 has extensive rodent data and three tiny human studies. TB-500 has no human data at all, and most of its animal data is on full-length thymosin beta-4. The ratio in the vial has never been studied.
- No research exists on the blend — only on the three components individually.
- GHK-Cu has the best-documented file of the three, largely in skin and wound healing.
- BPC-157 and TB-500 are the long-standing recovery pairing, strong in animals, with three tiny human studies for BPC-157 and none for TB-500.
- GHK-Cu typically accounts for most of the 70 mg by mass.
Watch: Glow Blend explained
Video by Peptide Buddy on YouTube. Not affiliated with Peptide Carl and not an endorsement — included because a second explanation of the same mechanism is often what makes it click.
Reported protocols
These are the doses the peptide community actually reports running (Reddit & forums), alongside published research — logged for education, not as a recommendation to use.
| Parameter | Commonly reported range |
|---|---|
| Typical vial | 70 mg total across the three components |
| Reconstitution | Blends generally take a larger volume — dosing is worked out per vial rather than per compound |
| Frequency | Usually follows the BPC/TB-500 cadence the components are individually run on |
| Route | Subcutaneous, rotating sites |
| Cycle | 4–8 weeks is the commonly described run |
| Community tip | Same fixed-ratio caution as any blend: you cannot adjust one component without moving all three. And most of the mass is GHK-Cu, so the actual BPC and TB-500 doses are well below what the 70 mg headline implies. |
Common use cases
| Goal | Community protocol notes |
|---|---|
| Repair with a skin component | the standard use — BPC/TB-500 cadence, 4–8 weeks |
| Convenience over control | one reconstitution instead of three |
| If inflammation is the target | KLOW adds KPV to the same three compounds |
Mixing it (reconstitution)
Freeze-dried peptides must be reconstituted with bacteriostatic water before they can be measured. Carl’s calculator turns “mg in the vial + ml of water + target dose” into “units on the syringe” — and tells you how long the vial lasts.
→ Open the Reconstitution Calculator
Injection & handling
Subcutaneous, rotating sites, following the practice used for the components individually. The blend arithmetic is the difference: your dose is a share of the whole vial, so reconstitution volume sets everything and no single component can be moved on its own. Blends usually take a larger reconstitution volume than a single-compound vial; the blends calculator works out what a given draw delivers of each component. Worth knowing that GHK-Cu carries most of the 70 mg, which means the BPC-157 and TB-500 amounts per injection are lower than the vial size implies. Refrigerate reconstituted and use within about 28 days.
Stacks it appears in
- It is already a stack — Adding BPC-157 or TB-500 on top duplicates what is already in the vial.
- KLOW instead — The same three compounds plus KPV, if an anti-inflammatory component is wanted.
Sources
- BPC 157 angiogenesis via VEGFR2, J Mol Med 2017 (PMID 27847966)
- BPC 157 tendon fibroblast migration, J Appl Physiol 2011 (PMID 21030672)
- BPC 157 gut review, Curr Pharm Des 2011 (PMID 21548867)
- Human evidence for BPC-157, systematic review, Acta Orthop Belg 2026 (PMID 42885452)
- TB-500 is Ac-LKKTETQ, J Chromatogr A 2012 (PMID 23084823)
- Active sites of thymosin beta-4, FASEB J 2010 (PMID 20179146)
- GHK-Cu stimulates collagen synthesis, FEBS Lett 1988 (PMID 3169264)
- GHK-Cu review, Int J Mol Sci 2018 (PMID 29986520)
- Topical GHK-Cu gel in diabetic ulcers, RCT, Wound Repair Regen 1994 (PMID 17147644)
- BPC-157 plus TB-500 in rat Achilles repair, Jt Dis Relat Surg 2026 (PMID 42542926)
- FDA: bulk substances that may present significant safety risks (Apr 2026)
